Clinical Trial Results:
Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in persons without cerebrovascular disease.
Summary
|
|
EudraCT number |
2016-001221-14 |
Trial protocol |
DK |
Global end of trial date |
02 Feb 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Nov 2020
|
First version publication date |
21 Nov 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
E.G.R.A.B.I.N.S1
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02838589 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Herlev Gentofte Hospital
|
||
Sponsor organisation address |
Borgmester Ib Juuls Vej 1, Herlev, Denmark, 2730
|
||
Public contact |
Christina Rostrup Kruuse, Herlev Gentofte Hospital, 45 38681233 , christina.rostrup.kruuse@regionh.dk
|
||
Scientific contact |
Christina Rostrup Kruuse, Herlev Gentofte Hospital, 45 38681233 , christina.rostrup.kruuse@regionh.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Apr 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
02 Feb 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
02 Feb 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective is to investigate the effect of a single dose of 5 mikrogram GLP-1 receptor agonist (exenatide) on cerebral blood flow velocity in humans without cerebrovascular disease.
|
||
Protection of trial subjects |
During the trial days, trial participants were monitored thoroughly with heart rate and blood pressure. They were asked how they felt every hour during the trial days and if they experienced any side effects. After the trial days, they were asked to complete a side effect form and then hand it in to the investigator. They were also given the phone number to the Department of Neurology, Herlev Gentofte Hospital (sponsor) which they could call to if they experienced any side effects or had any other trouble. If the participants experienced pain or distress during the trial days, we talked about it and tried to accomodate their wishes to see if we could minimize pain.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
24 Aug 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 36
|
||
Worldwide total number of subjects |
36
|
||
EEA total number of subjects |
36
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
25
|
||
From 65 to 84 years |
11
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
Participants were recruited from "http://www.forsoegsperson.dk", "www.sundhed.dk", and through advertisement. Participants were recruited year 2016 and 2017. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Screening was done by a medical doctor and a medical student. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Double blind | |||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst | |||||||||||||||
Blinding implementation details |
Exenatide was given sub-cutaneus by standard medication-pen. Placebo was given sub-cutaneus by a small syringe with a matching needle. Medication/placebo were given by a study nurse who was not blinded. The study nurse was not implemented in other parts of the trial. The participants were blindfolded when medication and placebo were delivered. Hence, investigator, subjects, data analyst and monitor were blinded.
|
|||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Exenatide | |||||||||||||||
Arm description |
Parallel-arm trial. Exenatide (5 ug) was given as a single dose. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Exenatide
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Byetta
|
|||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled pen
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
Dosage: 5 micrograms (ug)
Administration details: Sub-cutaneus injection by pen
|
|||||||||||||||
Arm title
|
Placebo | |||||||||||||||
Arm description |
Placebo (isotonic salt-water) was given sub-cutaneus by a small syrringe. | |||||||||||||||
Arm type |
Placebo | |||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
Dosage: 0,05 ml
Administration detail: Sub-cutaneus injection
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Exenatide
|
||
Reporting group description |
Parallel-arm trial. Exenatide (5 ug) was given as a single dose. | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Placebo (isotonic salt-water) was given sub-cutaneus by a small syrringe. | ||
Subject analysis set title |
Exenatide - baseline
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Exenatide group at baseline
|
||
Subject analysis set title |
Exenatide - 180 minutes
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Exenatide group at 180 minutes.
|
||
Subject analysis set title |
Placebo - baseline
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Placebo group at baseline.
|
||
Subject analysis set title |
Placebo - 180 minutes
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Placebo group at 180 minutes.
|
|
|||||||||||||||||||||
End point title |
Transcranial Doppler | ||||||||||||||||||||
End point description |
Changes in mean blood flow velocity in the middle cerebral artery before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
We performed TCD measurements at baseline and 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood pressure - diastolic | ||||||||||||||||||||
End point description |
Changes in blood pressure before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
We performed blood pressure measurements at baseline and 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood pressure - systolic | ||||||||||||||||||||
End point description |
Changes in blood pressure before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
We performed blood pressure measurements at baseline and 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
EndoPat - Regional hyperaemia index (RHI) | ||||||||||||||||||||
End point description |
Changes in regional hyperemia index before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
We performed EndoPAT measurements at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
EndoPat - augmentation index standardized to a heart rate of 75 (AI@75) | ||||||||||||||||||||
End point description |
Changes in EndoPAT - augmentation index standardized to a heart rate of 75 before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
We performed EndoPAT measurements at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Ankle brachial index | ||||||||||||||||||||
End point description |
Changes in ankel brachial index before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
We performed ankle brachial index measurements at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - 180 minutes v Placebo - baseline v Exenatide - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood glucose | ||||||||||||||||||||
End point description |
Changes in blood glucose before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood glucose were collected at baseline180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Placebo - baseline v Exenatide - 180 minutes v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood insulin | ||||||||||||||||||||
End point description |
Changes in blood insulin before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
We performed blood insulin measurements at baseline and 180 minutes postmedication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Placebo - baseline v Exenatide - 180 minutes v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
Blood c-peptide | ||||||||||||
End point description |
Blood c-peptide before exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at baseline.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
We performed blood c-peptide measurments at baseline.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
T-test | ||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||
Comparison groups |
Exenatide - baseline v Placebo - baseline
|
||||||||||||
Number of subjects included in analysis |
30
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
< 0.05 | ||||||||||||
Method |
t-test, 2-sided | ||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood sample - E-selectin | ||||||||||||||||||||
End point description |
Changes in biomarker concentration before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood samples were collected at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood sample - TNF-alpha | ||||||||||||||||||||
End point description |
Changes in biomarker concentration before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood samples were collected at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood sample - IL-6 | ||||||||||||||||||||
End point description |
Changes in biomarker concentration before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood samples were collected at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood sample - IL-1beta | ||||||||||||||||||||
End point description |
Changes in biomarker concentration before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood samples were collected at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood sample - VCAM1 | ||||||||||||||||||||
End point description |
Changes in biomarker concentration before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood samples were collected at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood sample - ICAM-1 | ||||||||||||||||||||
End point description |
Changes in biomarker concentration before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood samples were collected at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||
End point title |
Blood sample - VEGF | ||||||||||||||||||||
End point description |
Changes in biomarker concentration before and after exenatide/placebo for each subject were calculated and then further used for statistical analysis. Here, results are shown as the mean value and standard deviation for both groups at the different timepoints.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
Blood samples were collected at baseline and after 180 minutes post-medication.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
T-test | ||||||||||||||||||||
Statistical analysis description |
We performed a paired sample T-test.
|
||||||||||||||||||||
Comparison groups |
Exenatide - baseline v Exenatide - 180 minutes v Placebo - baseline v Placebo - 180 minutes
|
||||||||||||||||||||
Number of subjects included in analysis |
60
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
< 0.05 | ||||||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||||||
Confidence interval |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
During the whole trial period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Questionaire given to subjects. Subjects were asked to note all adverse events for 24 hours after medication administration.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
Events not coded | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
N/A
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Exenatide
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Exenatide (5 ug), single dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Placebo, single dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Exenatide - medication failure
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients who were supposed to recieve exenatide, but medication were given incorrectly which resulted in that no medication or a low dose were given instead. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0.05% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |